As Canada moves to ban asbestos, the Globe and Mail, a nationally distributed Canadian newspaper, published an article on the financial toll of asbestos related cancers. “This first-ever estimate pegs the cost of new cases at $1.7-billion per year in Canada, and notes that is likely an under-estimate”. Click here to read the news article.
There are gaps in physician knowledge concerning the guidelines for, and reimbursement of, low-dose CT (LDCT) lung screening that may apply to their patient population. A sample of family physicians that participated in completing a questionnaire indicated that most “discussed the risks/benefits of screening with their patients in some capacity (76%); however, more than 50% reported making 1 or no… Read more →
A few weeks ago Prime Minister Justin Trudeau made a commitment to banning asbestos in Canada, confirming the answer to a question posed by Fred Clare of the IAHFIAW. In support, more than 50 mesothelioma and lung cancer doctors sent a letter to the Mr. Trudeau and several MPs. Click here to read the article.
The pharmaceutical company Boehringer-Ingelheim has begun a clinical trial testing the use of a newer drug, initially approved for treating pulmonary fibrosis, to treat mesothelioma. This trial is recruiting patients willing to participate in research at eight sites in the U.S. and Canada. Click here to learn about the trial and to share with physicians.
In a May 2016 letter to the editor of the Annals of Occupational Hygiene doctors point out how important it is to understand a workers history of exposure to asbestos. Without your doctor knowing this information, there may be too many people with a diagnosis of “pulmonary fibrosis” that are not sufficiently monitored for the possibility of developing mesothelioma or… Read more →